Qualicaps acquires Genix Industria Farmaceutica, Brazil’s leading hard capsule manufacturer
The acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the US, to include Brazil.
Qualicaps has acquired Genix Industria Farmaceutica, Brazil’s leading two-piece hard capsule manufacturer with operations located in the pharmaceutical hub of Goais, and commercial activities managed from Sao Paulo.
Qualicaps is a global manufacturer of a complete assortment of two-piece hard capsules and related pharmaceutical processing equipment, belonging to Mitsubishi Chemical Holdings Corporation through The Life Sciences Institute, Inc., which encompasses its healthcare portfolio of businesses. With over a century of experience and a strong record of pioneering in new forms of drug administration, Qualicaps is responsible for several milestones in the history of hard capsule development, introducing features so widely accepted and trusted that they have since become standards in the pharmaceutical industry. The acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the US, to include Brazil.
Through Genix, Qualicaps will serve the pharmaceutical market in Latin America, valued by IMS Health at US$72 billion in 2014 and estimated to grow annually at an average of 5–8% through to 2019. The company will become the leading hard capsule manufacturer in the region and the only one with a production site in Brazil, the third largest pharmaceutical market in the Americas after the US and Canada, and eighth in the world. Genix currently supplies a large number of companies operating within the pharmaceutical and nutraceutical industry, and accounts for over half of Brazil’s market share in hard capsules.
In addition to a strong customer base, Genix brings to Qualicaps 13 years of experience in hard gelatin capsule manufacturing, and a robust process that is certified for Good Manufacturing Practice and Pharmaceutical Ingredients by ANVISA. From a financial perspective, consolidated figures are estimated to represent approximately a 7% growth in Qualicaps revenue in the short term, while in the long term the Americas region overall will increase in its overall contribution through planned future capacity increases. Kent M. Payne, President of Qualicaps Americas, comments to this regard: “This acquisition marks a major milestone for Qualicaps in positioning ourselves to provide a more complete coverage for our existing and potential pharmaceutical customers in the region. We look forward to continuing to accelerate our growth in Brazil and other Latin American countries as part of our overall strategic expansion plan for the Americas.”
The two companies already share an important synergy that enables their integration, as Genix has had a long-standing collaboration with Technophar, a wholly owned subsidiary of Qualicaps that provides the machinery and technology for both companies’ manufacturing processes.
“With Genix as part of the Qualicaps group of companies, we continue along the path marked by our vision of becoming the number one preferred partner to the pharmaceutical industry through addressing our customers’ needs and growth in the South American region,” comments Ciro Ahumada, Group CEO. He adds that “Genix fully complements the Qualicaps business, as it also has a strategical and operational focus on providing high-quality pharmaceutical-grade capsules along with scientific and technical support to our customers.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.